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Abstract
Objective: The telomerase RNA component (hTERC) gene is located at 3q26. Increased hTERC gene 
expression  has  been  frequently  observed  and  amplification  was  shown  using  fluorescence  in  situ 
hybridization (FISH) in different cancers. The aim of this study was to determine whether hTERC 
gene amplification is detectable by FISH in acute myeloid leukemia (AML) cells. 
Material and Methods: FISH and karyotype results at the time of diagnosis of 23 adult AML patients 
were retrospectively evaluated. Additionally, fixed cells were hybridized with an hTERC region-specif-
ic FISH probe to determine gene amplification.
Results: Ten of the 23 patients had a normal karyotype and 6 had an abnormal karyotype. hTERC 
region amplification was not observed in any of the patients. 
Conclusion: Although it was reported that hTERC gene amplification may partially contribute to 
increased telomerase expression and activity in leukemic cells, it is not possible to make such a conclu-
sion based on the results of the this study, as hTERC amplification was not observed in the study 
group. This suggests that increased telomerase activity via gene amplification in the development of 
AML may not be as important a factor as it is in solid tumors. (Turk J Hematol 2011; 28: 103-6)
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Özet
Amaç: Telomeraz RNA komponenti (hTERC) geni 3q26 bölgesinde yer alır. Çeşitli kanserlerde artmış 
hTERC gen anlatımı sıklıkla saptanmış ve FISH yöntemi ile gen amplifikasyonu gösterilmiştir. Bu 
çalışmanın amacı akut miyeloid lösemi (AML) hücrelerinde hTERC gen amplifikasyonunun FISH 
yöntemi ile saptanabilirliğinin araştırılmasıdır.
Yöntem ve Gereçler: Bu çalışmada 23 yeni tanı erişkin AML olgusunun FISH ve karyotip sonuçları 
geriye dönük olarak değerlendirildi. Ayrıca gen amplifikasyonunu değerlendirebilmek için tespit edil-
miş hücreler hTERC bölgesine özgül FISH probu ile melezlendi.Introduction
Acute myeloid leukemia (AML) originates from 
myeloid cells. The disease is characterized by rapid 
proliferation of abnormal cells, which accumulate 
in the bone marrow and interfere with the produc-
tion of normal blood cells. AML is the most com-
mon form of acute leukemia in adults and its inci-
dence increases with age [1]. Morphological, cyto-
chemical,  immunophenotypic,  cytogenetic,  and 
molecular features of the blasts are important fac-
tors in the classification of AML patients [2].
Telomeres, located at the ends of chromosomes, 
determine  the  replication  capacity  of  cells.  They 
shorten during each cell division and it is generally 
thought that telomere length serves as a clock for 
cells. Telomerase is a ribonucleoprotein complex, 
consisting of human transcriptase reverse transcrip-
tase (hTERT), proteins (hTP1), and RNA template 
for telomeric DNA synthesis (hTERC) [3]; this com-
plex  synthesizes  telomeres  and  stabilizes  their 
length. Mutations in any of these components may 
result  in  a  rare  bone  marrow  failure  syndrome 
known as dyskeratosis congenita [4].
Telomerase  activity  was  reported  to  be  low  in 
normal human somatic cells [3]. Proliferating cells 
become senescent when telomeres are short and 
when there is no telomerase activity. Cancer cells 
are known to overcome this senescence pathway 
and  become  immortalized.  Immortalization  is 
almost  always  accompanied  by  expression  of 
telomerase, which is most likely necessary for the 
continued  growth  of  cancer  cells.  Telomerase  is 
activated in most malignant tumours, but is usually 
inactive  in  normal  somatic  cells  [3].  Despite  the 
questionable role of telomerase reactivation in cell 
immortalization  and  carcinogenesis,  telomerase 
may serve as a diagnostic marker for tumor devel-
opment [5]. Several studies have shown that telom-
erase activity can be used to differentiate malignant 
from normal tissue in various organs; however, the 
majority of reports are devoted either to telomerase 
activity or expression [6]. The present study aimed 
to determine the presence of amplification of the 
hTERC  component  of  the  telomerase  complex  in 
cultured  bone  marrow  cells  obtained  from  AML 
patients. 
Materials and Methods
The study included bone marrow samples taken 
at the time of diagnosis from 23 AML adult patients 
between 2006 and 2008 that analyzed in our cytoge-
netics laboratory. Conventional cytogenetic analysis 
and FISH results for each patient were evaluated ret-
rospectively,  and  additional  hybridization  with  the 
hTERC  (3q26)/  3q11  probe  (Kreatech,  The 
Netherlands)  was  performed  to  determine  hTERC 
gene amplification. Slides were dehydrated in 70%, 
85%,  and  90%  alcohol  series,  consecutively,  and 
dried at room temperature. Denaturation and hybrid-
ization were carried out in a HyBrite denaturation/
hybridization system for FISH (Vysis, UK). The probe 
was denatured at 75°C for 5 min. Hybridization was 
carried out at 37°C for 14-16 h. After hybridization, the 
slides were washed in first post hybridization wash 
buffer at 73°C for 2 min, and then in second post 
hybridization wash buffer at room temperature for 1 
min and counterstained with DAPI. 
Signals  were  quantified  in  ≥200  cells  for  both 
hTERC gene and 3q11 signals under oil immersion 
at  1000×  magnification  using  the  recommended 
filters. Results are expressed as the ratio of hTERC 
signal (orange) to 3q11 signal (green). The expect-
ed  ratio  is  1:1;  which  indicates  there  is  no  gene 
amplification and when the ratio of signals is ≥2:1, 
it  indicates  hTERC  gene  amplification  (Figure  1). 
Our  samples  were  chosen  from  archive  material 
consisting of patient samples who approved mate-
rial useage after diagnostic procedures.
Bulgular: Çalışma kapsamına alınan 23 hastanın 10’unda normal karyotip; 6 hastada anormal karyo-
tip bulundu. Hastaların hiçbirinde hTERC bölgesinde gen amplifikasyonu saptanamadı.
Tartışma: Hasta grubumuzda hTERC amplifikasyonu bulmadık. Bu nedenle, hTERC gen amplifikas-
yonunun lösemik hücrelerde telomeraz anlatımı ve aktivitesini arttırmada kısmen etkili olduğunun 
bildirilmesine karşın, çalışmamızın sonuçları ile benzer bir sonuca ulaşmak mümkün olmamıştır. Bu 
sonuç, AML gelişiminde gen amplifikasyonu yoluyla telomeraz aktivite artışının, solid tümörlerde 
olduğu kadar önemli bir faktör olmadığı görüşünü destekler niteliktedir. (Turk J Hematol 2011; 28: 103-6)
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Among  the  23  patients,  14  (60.9%)  were  male 
and  9  (39.1%)  female;  median  age  was  49  years 
(range: 15-76 years). Conventional cytogenetic and 
routine  FISH  results  are  given  in  the  Table  1. 
Cytogenetic analysis was not possible in 7 patients 
due to culture failure or because we did not find 
suitable  metaphases  for  chromosome  analysis 
(shown  in  the  Table  as  N/A).  In  all,  10  of  the  23 
patients  had  a  normal  karyotype  and  6  had  an 
abnormal  karyotype.  The  observed  abnormalities 
included trisomy 8, t(1;3), der(7), t(15;17), del(5), 
and  inv(16).  We  did  not  observed  any  complex 
karyotypes  and  the  above-mentioned  cytogenetic 
defects were the only abnormality in each patient. 
Routine FISH analysis showed that 5 patients had 
t(15;17), 2 patients had t(8;21), 1 patient had triple 
signal for the 8q22 region, 1 patient had a deletion 
in  the  5q31  region,  and  1  patient  had  inv(16). 
According to FISH analysis, none of the patients had 
hTERC gene amplification. 
Discussion
Normal human cells have low levels of telomer-
ase  expression;  however,  when  telomere  length 
reaches  a  critical  point  abnormal  activation  of 
telomerase can lead to immortalization and uncon-
trolled proliferation. This process is associated with 
the development of many leukemias and lympho-
mas  [8].  More  than  80%  of  various  cancers  have 
increased  telomerase  activity,  and  it  has  been 
reported that amplification of the telomerase gene 
might play a role in telomerase reactivation, which 
leads  to  cell  immortalization  and  seems  to  be  a 
common event in carcinogenesis [9].
It has been reported that increased hTERT and/or 
hTERC gene expression may be an important mech-
anism  involved  in  upregulated  telomerase  activity. 
Accordingly,  investigation  of  hTERT  and/or  hTERC 
amplification might be useful in the diagnosis and 
follow-up  of  cancer  patients  [10].  In  the  present 
study we only examined amplification of the hTERC 
component, as it is known that hTERC gene amplifi-
cation  alone  can  result  in  increased  telomerase 
activity [10]. Further investigation of hTERT amplifi-
cation may be useful for elucidating the interactions 
of these genes in the progression of AML.
hTERC gene expression can be affected by and 
regulated by various processes inside cells; namely, 
gene  amplification,  transcriptional  regulation,  and 
epigenetic modification [11]. It was suggested that 
the high-level of expression and activity of telomer-
ase observed in acute leukemia cells might be due 
to hTERC gene amplification, which is localized at 
3q26.3. FISH is a useful method for observing gene 
amplification and was used in the present study to 
determine  hTERC  gene  amplification.  Previous 
studies have reported that amplification of hTERT 
and hTERC genes in acute leukemia cells exhibit a 
variable number of copies-as many as 12-based on 
FISH analysis [12].
One study that included patients with different 
types of leukemia subgroups reported that amplifi-
cation of hTERC and hTERT genes was associated 
with increased telomerase activity and expression 
in leukemia cells [12]. Hematologic malignancies 
differ from other cancers, as they do not originate 
from  cells  with  low-level  telomerase  activity. 
Serakinci et al. reported that there was no amplifi-
cation of the hTERT region in patients with mono-
somy 7 and no deletion at 7q31 [13]. In the present 
study  1  patient  had  a  derivative  chromosome  7 
(patient No. 10), which we think originated from a 
translocation with an undefined chromosome. The 
fact  that  we  did  not  observe  amplification  of  the 
hTERC region in this patient supports the notion that 
this amplification may not be a characteristic of leu-
kemia cells with an abnormality in chromosome 7. 
Nonetheless, the unknown chromosomal compo-
nent of the translocation and the putative effector 
genes on the derivative chromosome 7 should not 
be overlooked.
Figure 1. Normal AML cells for hTERC gene amplification analysis 
using FISH. The specific molecular probe for hTERC was labeled 
with rhodamine (Spectrum Orange) and the 3q11 reference probe 
was labeled with fluorescein (Spectrum Green)
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gation  of  hTERC  gene  amplification  and  frequent 
genetic changes could further delineate the tumor 
biology  and  might  be  useful  for  determining  the 
prognostic  factors  in  AML.  In  the  present  study 
hTERC  gene  amplification  in  the  bone  marrow 
samples was not observed, based on FISH analysis. 
Given the limited number of cases included, it is not 
possible to definitively conclude that hTERC gene 
amplification has any impact on the clinical course 
of AML or that its amplification based on FISH could 
be used as a diagnostic marker; however, the pres-
ent results are in agreement with those of previous 
studies that have suggested that increased telomer-
ase activity due to telomerase gene amplification 
may not be as influential in leukemias as in solid 
tumors  [13].  Additional  research  (with  larger 
patients  groups)  on  the  expression  of  the  hTERC 
gene  and  other  components  of  the  telomerase 
complex is warranted. 
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Table 1. The patients, and their conventional cytogenetic and FISH results
Patient   Sex  Age  Karyotype  FISH panel
Number 
1  E  76  N/A  Normal
2  E  15  47,XY,+8  8q22 triple  
        signal
3  E  24  46,XY,t(1;3) (p36.3;q21)  Normal 
4  K  64  N/A  Normal
5  E  27  Normal  Normal
6  K  28  N/A  t(15;17) +
7  K  34  N/A  t(15;17) +
8  K  50  Normal  t(15;17) + 
9  E  49  Normal  Normal
10  E  47  46,XY,der(7)t(7;?)  t(8;21) +
      (q32;?),t(8;21)(q22;q22)  
11  E  33  46,XY,t(15;17)(q22;q21)   t(15;17) +
12  E  55  N/A  Normal
13  E  52  N/A  t(8;21) +
14  E  37  46,XY,del(5)(q31)  Deletion 5q31
      [16]/46,XY[2]    
15  K  50  Normal  Normal
16  E  75  46XY,inv(16) (p13q22 )  inv(16) +
      [4]/46,XY[1]  
17  E  27  Normal  Normal
18  E  46  N/A  Normal
19  E  53  Normal  Normal
20  K  39  Normal  Normal 
21  K  57  Normal  Normal
22  K  58  Normal  t(15;17) +
23  K  65  Normal  Normal
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